These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9740070)

  • 1. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis.
    Böttger TC; Youssef V; Dutkowski P; Maschek H; Brenner W; Junginger T
    Cancer; 1998 Sep; 83(6):1074-80. PubMed ID: 9740070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD44v5 and -v6 in Barrett's carcinoma is not increased compared to that in nondysplastic Barrett's mucosa.
    Menges M; Goebel R; Pueschel W; Zeitz M; Stallmach A
    Exp Mol Pathol; 2002 Jun; 72(3):207-12. PubMed ID: 12009784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CD44 in premalignant and malignant Barrett's oesophagus.
    Lagorce-Pages C; Paraf F; Dubois S; Belghiti J; Fléjou JF
    Histopathology; 1998 Jan; 32(1):7-14. PubMed ID: 9522210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
    Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
    [No Abstract]   [Full Text] [Related]  

  • 6. [Expression of CD44 and isoforms v4, v5, v6, v7, v10--new prognostic parameters in ductal pancreatic carcinoma?].
    Böttger T; Maschek H; Gottwald W; Lobo M; Brenner W; Junginger T
    Chirurg; 1998 Oct; 69(10):1089-92. PubMed ID: 9833191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta 1 integrin expression in adenocarcinoma of Barrett's esophagus.
    Bottger TC; Youssef V; Dutkowski P; Seifert J; Maschek H; Brenner W; Junginger T
    Hepatogastroenterology; 1999; 46(26):938-43. PubMed ID: 10370643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.
    Nakamura T; Nekarda H; Hoelscher AH; Bollschweiler E; Harbeck N; Becker K; Siewert JR; Harbec N [corrected to Harbeck N]
    Cancer; 1994 Apr; 73(7):1785-94. PubMed ID: 7907940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of tumor ploidy and histomorphological parameters in adenocarcinoma of Barrett's esophagus.
    Böttger T; Dutkowski P; Kirkpatrick CJ; Junginger T
    Dig Surg; 1999; 16(3):180-5. PubMed ID: 10436364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemoradiotherapy alters the expression and prognostic significance of adhesion molecules in Barrett's-associated adenocarcinoma.
    Turner JR; Torres CM; Wang HH; Shahsafaei A; Richards WG; Sugarbaker D; Odze RD
    Hum Pathol; 2000 Mar; 31(3):347-53. PubMed ID: 10746678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.
    Popnikolov NK; Gatalica Z; Adegboyega PA; Norris BA; Pasricha PJ
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):161-5. PubMed ID: 16785783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
    Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
    Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux.
    Agarwal B; Swisher SG; Ajani J; Kelly K; Komaki RR; Abu-Hamda E; Correa AM; Roth JA
    Ann Thorac Surg; 2005 May; 79(5):1716-23. PubMed ID: 15854962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
    von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
    Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.
    Hardikar S; Onstad L; Song X; Wilson AM; Montine TJ; Kratz M; Anderson GL; Blount PL; Reid BJ; White E; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2393-403. PubMed ID: 25106775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
    Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
    Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus.
    Hamilton SR; Smith RR
    Am J Clin Pathol; 1987 Mar; 87(3):301-12. PubMed ID: 3825997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.